These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33489809)

  • 21. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report.
    Yang Y; Zheng H; Li Z; Shi S; Zhong L; Gong L; Lan B
    Front Oncol; 2022; 12():841493. PubMed ID: 35664754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.
    Vavalà T; Mariniello A; Novello S
    Transl Cancer Res; 2019 Jan; 8(Suppl 1):S48-S54. PubMed ID: 35117063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durable clinical response to ALK tyrosine kinase inhibitors in
    Hu H; Dai H; Ding L
    Transl Cancer Res; 2022 Aug; 11(8):2967-2972. PubMed ID: 36093526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report.
    Feng C; Zhou R; Liu F; Wang T; Liu S; Shao Y
    Front Oncol; 2021; 11():700341. PubMed ID: 34490099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.
    Xu X; Liu D; Wen J; Chen J; Fan M
    Transl Lung Cancer Res; 2020 Dec; 9(6):2500-2507. PubMed ID: 33489810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.
    Zhai X; Wu Q; Pu D; Yin L; Wang W; Zhu D; Xu F
    Front Oncol; 2021; 11():782682. PubMed ID: 35070986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to erlotinib in a patient with lung adenocarcinoma harbouring the
    Alì G; Chella A; Lupi C; Proietti A; Niccoli C; Boldrini L; Davini F; Mussi A; Fontanini G
    Oncol Lett; 2015 Apr; 9(4):1537-1540. PubMed ID: 25788996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency, clinical features and differential response to therapy of concurrent
    Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
    Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
    [No Abstract]   [Full Text] [Related]  

  • 32. Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple
    Wei Q; Zhang Y; Wang Y; Desai A; Tan S; Huang Q; Pu X; Tian P; Li Y
    Transl Lung Cancer Res; 2023 Sep; 12(9):1935-1948. PubMed ID: 37854161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
    Pagan C; Barua S; Hsiao SJ; Mansukhani M; Saqi A; Murty V; Fernandes H
    Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer.
    Kang J; Zhang XC; Chen HJ; Zhong WZ; Xu Y; Su J; Zhou Q; Tu HY; Wang Z; Xu CR; Yang XN; Chen ZH; Wu X; Zhang X; Shao Y; Wu YL; Yang JJ
    Front Oncol; 2020; 10():596937. PubMed ID: 33363027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
    Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report.
    Shi J; Jia Z; Zhou Z; Zhao L; Meng Q; Liu Y
    Onco Targets Ther; 2023; 16():109-114. PubMed ID: 36824323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.